Future Tech/consumer
Continuous Health Monitoring Becomes the Default Wellness Layer
Dexcom Stelo lets non-diabetics wear a glucose monitor. Whoop, Oura, Apple Watch track sleep and HRV. By 2029 most adults have continuous biomarker data.
// By 2029 · medium confidence · disruption 8/10
Prediction
// 2029
By 2029, the majority of US adults with health insurance will wear at least one continuous health monitoring device. Healthcare data infrastructure rebuilds around streaming biometric data.
What dies
- → the pager
Who wins
- → Apple
- → Dexcom
- → Whoop
The hook
Dexcom launched Stelo in 2024, an OTC continuous glucose monitor for non-diabetics. Abbott launched Lingo. Whoop has millions of paying subscribers. Continuous health data went from niche-medical to consumer-mainstream in about 18 months.
Thesis. Continuous health monitoring is the most important consumer health shift since the smartphone. Episodic care becomes continuous care. Your devices flag issues before symptoms appear.
The story
The current state
Apple Watch has five-plus FDA-cleared features (ECG, blood oxygen, irregular heart rhythm, fall detection, sleep apnea screening). Oura subscribers exceed 2.5 million. Whoop revenue passed $400M. Dexcom Stelo and Abbott Lingo brought CGMs to non-diabetics in 2024.
The inflection point
The OTC biomarker shift (2023 to 2025) was the unlock. Continuous glucose, sleep stages, HRV, blood pressure rings, and ECG are now consumer-accessible without prescription in most cases. The data pipelines (Apple Health, Google Fit, Samsung Health) became real platforms.
The prediction
By 2029, most insured US adults wear at least one continuous monitor. AI synthesizes the streams into a personal health profile. Healthcare workflows incorporate the data. Insurance pricing adjusts for verified continuous-monitoring participation.
Who wins, who loses
Winners: Apple, Dexcom, Whoop, Oura, Abbott, Garmin, and the AI vendors that synthesize streams into clinical signal. Losers: the pager as a clinical communication device, the episodic-only visit as primary care, and the assumption that healthcare data lives in the clinic.
Timeline and risks
Adoption is fast. Integration into clinical care lags. The biggest open question is data: HIPAA was built for episodic clinical records, not for continuous consumer biometric streams. The regulatory framework needs to catch up.
First signals (verify today)
Dexcom Stelo FDA cleared for non-diabetics 2024. Abbott Lingo OTC 2024. Oura at 2.5M+ subscribers. Apple Watch FDA-cleared features expanding.
Key data points
- Dexcom Stelo OTC FDA clearance: March 2024
- Abbott Lingo OTC launch: 2024
- Oura subscribers: 2.5M+ by 2024
- Whoop revenue: $400M+
- Apple Watch FDA-cleared features: 5+
Contrarian angle
The HIPAA framework was built for episodic clinical data. Continuous biometric streams from consumer devices fall outside HIPAA in most cases. The most sensitive health data of millions of people sits in consumer cloud infrastructure with no clinical-grade protection requirement. The CIAM industry should be paying close attention because this is identity infrastructure applied to a category that does not realize it needs it.
The flip side
What this kills
The paired obituary in Tech Graveyard.
Read the obituaryFAQ
Are continuous glucose monitors actually useful for non-diabetics?
Useful for understanding individual glucose response to foods, sleep, and stress. Less clearly useful as a long-term health intervention for already-healthy adults. The clinical evidence is still developing.
Is the data from Oura or Whoop covered by HIPAA?
Generally no. Consumer device data sits outside HIPAA unless explicitly shared with a covered entity. This is the regulatory gap that gets closed in the next five years.
Will continuous monitoring change health insurance pricing?
Yes, especially in life and supplemental health. Group health is constrained by ACA rules. Expect verified-monitoring premium credits to expand.
How does AI use continuous biometric data?
Pattern detection (atrial fibrillation, sleep apnea), trend analysis (cardiovascular drift), and anomaly flagging before symptoms appear. The clinical workflow integration is the open work.
More from guptadeepak.com
Want the technical deep-dive behind this prediction?
Read the companion articleRelated predictions
More from the consumer desk.
// By 2032
medium confidenceKids Born After 2020 Will Not Need a Driver's License
Waymo runs 200,000+ weekly trips with no driver. Tesla, Zoox, and Chinese players scale fast. By 2032 the question is not whether kids learn to drive, but where they would need to.
First signals: Waymo at 200,000+ weekly rides across 5+ cities. Tesla FSD v13 shipping. Wayve raised $1B. Mercedes Drive Pilot Level 3 in production.
consumer · Disruption 10/10
// By 2031
medium confidenceRobotaxis Become Default Urban Transport
The question is not whether your kids will drive. It is whether they will need to own a car at all. By 2031 most urban trips in major US and Chinese cities will be robotaxi-summoned.
First signals: Waymo 200K+ weekly rides. Baidu Apollo Go expanding to 10+ Chinese cities. Tesla robotaxi service plans 2026. Lyft and Uber inking robotaxi-fleet deals.
consumer · Disruption 10/10
// By 2028
high confidenceSmart Homes That Actually Work via Matter
Smart home has been broken for 15 years because of standards wars. Matter ended the war. Apple, Google, Amazon, Samsung all back the same standard. The category finally works.
First signals: Matter 1.0 launched 2022. Matter 1.4 launched 2024 with energy management. Major retailers tag products as Matter-compatible.
consumer · Disruption 6/10